Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Actemra IV (tocilizumab) • RG6129